Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O60663
UPID:
LMX1B_HUMAN
Alternative names:
LIM/homeobox protein 1.2; LIM/homeobox protein LMX1B
Alternative UPACC:
O60663; F8W7W6; O75463; Q5JU95; Q6ISC9
Background:
The LIM homeobox transcription factor 1-beta, known as LMX1B, plays a pivotal role in the regulation of podocyte-expressed genes, crucial for kidney function. It is also essential for specifying dorsal limb fate, influencing skeletal patterning. Alternative names include LIM/homeobox protein 1.2 and LIM/homeobox protein LMX1B.
Therapeutic significance:
LMX1B's involvement in diseases such as Nail-patella syndrome and Focal segmental glomerulosclerosis 10 highlights its therapeutic potential. Understanding the role of LMX1B could open doors to potential therapeutic strategies for these conditions, offering hope for patients suffering from abnormal skeletal patterning, renal dysplasia, and progressive decline in renal function.